Arrowhead concludes enrolment for Phase III zodasiran trial in HoFH

Phase 3zodasiranPositive

AI Analysis

Summary

Arrowhead Pharmaceuticals has completed patient enrolment in the global Phase III YOSEMITE study evaluating zodasiran for the treatment of homozygous familial hypercholesterolemia. The trial completion represents a milestone in the development program.

Clinical Trial Data

Phase

Phase III

Outcome Details

Patient enrolment completed in YOSEMITE Phase III study

Importance:5/10

Sentiment:

0.30

Phase IIIzodasiranHoFHYOSEMITE trialenrollment complete

Related Companies

$ARWR

Read the original article

Published by Clinical Trials Arena on July 28, 2026 9:40 AM

Read Original